Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Vivoryon Therapeutics N.V., a clinical stage biotechnology company, successfully held its Annual General Meeting, with shareholders approving all agenda items. The company, which specializes in small molecule medicines for diseases like Alzheimer’s and cancer, has made all AGM-related documents available on its website.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.